Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study.
Fumika ShigiyamaNaoki KumashiroAyako FuchigamiTakahisa HirosePublished in: Cardiovascular diabetology (2018)
There is lack of solid information on differences in the therapeutic effects of SGLT2 inhibitors and DPP4 inhibitors on multiple risk factors for cardiovascular diseases. It is anticipated that the results of the DIVERSITY-CVR study provides useful clinical data on the management of patients with T2DM, including reducing the risk of CVD. The results of this study will become available in 2019. Trial registration University Hospital Medical Information Network Clinical Trial Registry (UMIN000028014). Registered 30 June 2017.
Keyphrases
- type diabetes
- clinical trial
- cardiovascular risk factors
- cardiovascular disease
- healthcare
- ejection fraction
- randomized controlled trial
- machine learning
- skeletal muscle
- metabolic syndrome
- insulin resistance
- prognostic factors
- chronic kidney disease
- open label
- patient reported outcomes
- phase iii
- cardiovascular events